EpiEndo Pharmaceuticals secured $910k from new and existing investors
EpiEndo Pharmaceuticals, a Reykjavik, Iceland-based pharmaceutical company focused on novel solutions for chronic airway diseases, announced the completion of a ISK 110 million ($910k) investment round.
The financing was led by a syndicate of funds and angel investors. Existing investors also substantially participated in this financing.
The funds will be used to advance the pre-clinical development of the our lead program of proprietary products called “Barriolides” for the treatment of Chronic Obstructive Pulmonary Disease (COPD), the leading respiratory disease with over 70 million patients worldwide that has significant unmet medical need and is an increasing burden globally.
EpiEndo Pharmaceuticals, founded in 2014 and led by CEO Fredrik Lehmann, is developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. The company is focusing on chronic respiratory diseases with its first clinical trials planned in 2020.